"Development of this compound for human use would provide a non-surgical way to actually reduce accumulated white fat, in contrast to current weight-loss drugs that attempt to control appetite or prevent absorption of dietary fat," says Renata Pasqualini, Ph.D., professor in MD Anderson's David H. Koch Center for Applied Research of Genitourinary Cancers.
"We're greatly encouraged to see substantial weight loss in a primate model of obesity that closely matches the human condition," Pasqualini says.
Treated monkeys had corresponding reductions in waist circumference and body mass index. Untreated control monkeys were largely unchanged during the study.
Imaging studies showed treated monkeys lost 38 % of their body fat, including 27 % of their abdominal fat, indicating that weight loss was caused by fat reduction and not the loss of other types of tissue.